1. Zirabev, manufactured by Pfizer, is a biosimilar to Avastin, a treatment for metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and metastatic cervical cancer.
2. Soliris, an injection, was approved for the treatment of neuromyelitis optica spectrum disorder, a rare autoimmune disease affecting the central nervous system.
3. Dupixent is the first treatment approved for chronic rhinosinusitis with nasal polyps, which are growths on the inner lining of sinuses.
4. Vyleesi, an under-the-skin injection, is a treatment for premenopausal women with hypoactive sexual desire disorder. It is intended to increase desire in women who experience “low sexual desire that causes marked distress or interpersonal difficulty.”
5. The FDA expanded approval of Symdeko, tablets that treat cystic fibrosis, to include patients ages 6 years and older. Symdeko was previously approved for use in patients ages 12 and older.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.